AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04408989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02-SP
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Study NCT04408989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02-DM
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Study NCT04408989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US licenced Avastin®
Description: Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion
Study NCT05015426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Delta T-Cell Infusion
Description: Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.
Study NCT06277687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual Augmented Reality Combined With Finder
Description: After CT examination, the computer carried out three-dimensional reconstruction of blood vessels, and input the CTA data into Cinematic Anatomy reconstruction software to analyze blood vessels, Muscles and other tissues are reconstructed in three dimensions. Before the operation, the Finder is used to restore the position of the thigh during CTA examination. The Hololens is used to match the reconstructed three-dimensional image with the perforator locator and the thigh. Before the operation, the pedicles of the descending branches of the lateral arteries and the perforating vessels are marked on the skin of the thigh to achieve the positioning and marking of the perforating branches.
Study NCT04232566 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Evaluate liver fibrosis by elastography before gastric bypass surgery.
Study NCT06261021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% cream
Description: Topical application of Ruxolitinib 1.5% cream
Study NCT06261021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application without occlusion in Area 1
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.
Study NCT06261021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application under occlusion at night in Area 2
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.
Study NCT06261021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application under occlusion at night in Area 1
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.
Study NCT06261021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application without occlusion in Area 2
Description: Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.
Study NCT04672239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone app Smiling instead of Smoking (SiS) Version 3
Description: Participants will be onboarded to the smartphone app SiS and will be asked to use it for 7 weeks to support them in quitting smoking.
Study NCT04672239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone app QuitGuide (QG)
Description: Participants will be onboarded to the NCI smartphone app QG and will be asked to use it for 7 weeks to support them in quitting smoking.
Study NCT04672239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brochure Clearing the Air (CTA)
Description: Participants will be onboarded to the brochure Clearing the Air and will be asked to use it for 7 weeks to support them in quitting smoking.
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend telephone-based coaching sessions
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive written educational materials on physical activity and standard preoperative care
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive a personalized physical activity program, set fitness goals
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity monitor
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear activity monitor
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06196008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04074044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BHmApp
Description: Use of BHmApp for bladder education and training in pregnancy
Study NCT05760365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed educational model
Description: 3D printed cardiac catheterization model
Study NCT05760365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slide-based presention
Description: Slide-based presention
Study NCT05857995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program
Description: KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.
Study NCT05857995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.
Study NCT06132243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jaktinib Hydrochloride Tablets
Description: Orally, one tablet at a time
Study NCT06132243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Orally, one tablet at a time
Study NCT06372678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection
Study NCT06372678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04866446 — intervention group
Intervention type: DEVICE
Intervention: endotracheal intubation and laringeal mask airway insertion
Description: endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices
Study NCT06407414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: classical physiotherapy methods
Study NCT06407414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: In addition to classical physiotherapy methods, neuromuscular exercise protocol will be applied.
Study NCT06002919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MindWalk Intervention
Description: The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
Study NCT06052319 — intervention group
Intervention type: DEVICE
Intervention: Care4Today® Connect CAD-PAD Mobile Application
Description: Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.
Study NCT05194124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 2 mg
Description: Administered as SC injection
Study NCT05194124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 2.5 mg
Description: Administered as SC injection
Study NCT05194124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 3 mg
Description: Administered as SC injection
Study NCT05194124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 20 mg
Description: Administered as SC injection
Study NCT05194124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 25 mg
Description: Administered as SC injection
Study NCT05194124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide 30 mg
Description: Administered as SC injection
Study NCT05023681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Staphylokinase
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study NCT05023681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study NCT05031663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond group
Description: Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
Study NCT05031663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
Study NCT04727268 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No interventions present in this study.
Study NCT05769569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: VRC07-523LS is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site. Intravenous infusion of 10 mg/kg VRC07-523LS will be administered on Week 0.
Study NCT05769569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region. Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.
Study NCT05769569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 is a recombinant human superagonist interleukin-15 (IL-15) complex. N-803 at 6 ug/kg will be administered via subcutaneous injection to the trunk on Weeks 1, 4, 7, 39, 42 and 45.
Study NCT05769569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV is a tetravalent vaccine comprising Ad26.Mos1.Env, Ad26.Mos2S.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol. Ad26.Mos4.HIV at 5x1010 viral particles (per 0.5 mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 11.
Study NCT05769569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-HIV
Description: MVA-BN-HIV is a single vector recombinant Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) expressing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol. MVA-BN-HIV at 2x108 infectious unit (per 0.5mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 35.
Study NCT05769569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A244d11 gp120
Description: A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine. A244d11 gp120 at 300 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
Study NCT05769569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALFQ
Description: ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21. ALFQ at 200 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
Study NCT05769569 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Description: This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
Study NCT05769569 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Therapy (ART)
Description: This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
Study NCT06127823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Description: Dietary counselling
Study NCT06127823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary treatment
Description: Dietary counselling
Study NCT05011773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Electrical pulses from implanted generator that has already been implanted for therapeutic reasons
Study NCT06203015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Cambridge Neuropsychological Test Automated Battery.
Description: to determine cognitive dysfunction
Study NCT06203015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples
Description: to measure levels of cytokines, endotoxin, and genetic markers.
Study NCT06203015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: brain MRI
Description: to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations
Study NCT06203015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the Montgomery-Åsberg Depression Rating Scale
Description: to measure severity of depressive symptoms
Study NCT06203015 — intervention group
Intervention type: OTHER
Intervention: questionnaire prepared by the researchers
Description: collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
Study NCT05893628 — intervention group
Intervention type: OTHER
Intervention: muscle length and muscle endurance assessment
Description: Pectoralis Minor Length and muscle endurance evaluation
Study NCT05324358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
Study NCT05324358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine single use vials at 4 mg/mL, filled with 1 mL.
Study NCT05324358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Placebo for NTM-001
Description: Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
Study NCT05324358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo for NTM-001
Description: Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).
Study NCT05324358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV Placebo for Morphine
Description: Placebo single use vials with saline (matching active morphine).
Study NCT05324358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo for Morphine
Description: Placebo single use vials with saline (matching active morphine).
Study NCT06498349 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment
Description: according to widely accepted expert consensus paper
Study NCT06498349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations
Description: according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
Study NCT06555406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating for 8 weeks
Description: limiting food intake to 10 hours per day
Study NCT06487611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A humanoid social robot
Description: A humanoid social robot-mediated programme, including human-robot interactions, listening songs and daily news, doing physical activities and play memory games
Study NCT05730023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);
Study NCT05730023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized language training
Description: individualized language training
Study NCT05730023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individualized language training
Description: individualized language training
Study NCT05730023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tDCS
Description: Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
Study NCT05370651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella Chair
Description: Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
Study NCT05370651 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL Emsella Chair
Description: Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
Study NCT05308537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Compassion Care Program
Description: The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
Study NCT05917899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Family-Centered Rounds
Description: The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and \[if in attendance\] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
Study NCT04746391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer type
Description: Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers
Study NCT04746391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis duration
Description: Fiber blocking and dialyzer clearance is calculated for three different dialysis durations
Study NCT05907174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siyakhana - P
Description: A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
Study NCT05927818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer
Description: Described in previous sections